As part of our purpose to serve overlooked patients, we’re sharing that an FDA-approved ready-to-use oral solution for treating ADHD in adults and pediatric patients 6 years and older will be available mid-2026. #overlookedpatients#ADHD Learn more: https://t.co/x0057jaAsN
BREAKING NEWS: ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
hashtag #overlookedpatients https://t.co/39whtoXqXA
Even with multiple options for #hypertension, ~33M Americans still have high #bloodpressure despite treatment. Watch the @HCPLiveNews full interview with Paul Whelton, MD, here👉 https://t.co/4X0OsGqfd3
We're heading to Las Vegas, NV for the 2025 ASHP Midyear Clinical Meeting (December 8-10). Come visit us at Booth #654 to learn more about how Azurity is serving overlooked patients. #ASHP25#OverlookedPatients
We're heading to Chicago, IL for the 2025 Radiological Society of North America annual meeting (Nov 30-Dec 4). Come visit us at Booth #3578 to learn more about how Azurity is serving overlooked patients. #RSNA25#OverlookedPatients
Innovation meets impact! Azurity Pharmaceuticals is excited to announce Ogilvy Health as our new PR and Marketing Agency of Record. Read more here: https://t.co/4fUSfp6qC0 #HealthcareMarketing#PR#BrandStrategy
BREAKING NEWS: Azurity Pharmaceuticals Announces the FDA Approval of Ferabright™ (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain #overlookedpatients#MRI
https://t.co/8bWziSCQbD